Properties
What is it?
International Nonproprietary Name - latanoprost Clinical-pharmacological group: Ophthalmology → Anti-glaucoma agents → For topical use in ophthalmology → F2 alpha prostaglandin analogs Composition 1 ml of solution contains: Active substance: latanoprost 50 mcg; Excipients: sodium chloride, sodium dihydrogen phosphate (monohydrate), sodium hydrogen phosphate (anhydrous), benzalkonium chloride, water for injection. Indications Reduction of elevated intraocular pressure in patients with open-angle glaucoma or elevated ocular tension. Dosage and Administration Adults (including elderly) - one drop in the affected eye, once a day. Optimal effect is achieved when the preparation is used in the evening. Side Effects The following adverse reactions have been reported with the use of the preparation: Organ of vision: eye irritation (burning sensation, gritty sensation in the eyes, stinging and foreign body sensation); blepharitis, conjunctival hyperemia, eye pain; increased iris pigmentation, transient punctate epithelial erosions, eyelid edema, corneal edema and erosions, conjunctivitis, eyelash lengthening, thickening, increased density and pigmentation; iritis/uveitis; keratitis; macular edema, including cystoid; change in eyelash growth direction, rarely causing eye irritation; blurred vision. Skin and subcutaneous tissue: rash, darkening of eyelid skin and local skin reactions on the eyelids. Nervous system: dizziness, headache. Respiratory organs: asthma (including acute attacks or exacerbation of the disease in patients with a history of bronchial asthma); shortness of breath. Musculoskeletal and connective tissue: muscle/joint pain. Non-specific reactions: non-specific chest pain. Contraindications Hypersensitivity to latanoprost or other components of the preparation. Age under 18 years. Precautions Aphakia, pseudophakia with rupture of the posterior lens capsule, patients with a known risk of macular edema (macular edema, including cystoid, has been described during latanoprost treatment); inflammatory, neovascular or congenital glaucoma (due to insufficient experience with the use of the preparation). Pregnancy and Lactation Adequate controlled studies in pregnant women have not been conducted. The administration of the preparation during pregnancy is permissible only when the potential benefit to the mother outweighs the possible risk to the fetus. Latanoprost and its metabolites may be excreted in breast milk, so the use of the preparation during breastfeeding should be done with caution. Overdose Apart from irritation of the ocular mucous membrane, conjunctival or episcleral hyperemia, no other adverse effects on the organs of vision are known in case of latanoprost overdose. In case of accidental oral intake of latanoprost, the following information should be considered: one vial with 2.5 ml of solution contains 125 mcg of latanoprost. More than 90% of the preparation is metabolized in the liver during the first pass. Intravenous infusion at a dose of 3 mcg/kg in healthy volunteers did not cause any symptoms, however, at doses of 5.5-10 mcg/kg, nausea, abdominal pain, dizziness, weakness, and sweating were observed. In patients with moderate bronchial asthma, administration of latanoprost at a dose 7 times higher than the therapeutic dose did not cause bronchospasm. In case of overdose, symptomatic therapy is carried out.